Please provide your email address to receive an email when new articles are posted on . A single burst of antitachycardia pacing (ATP) reduced risk for shocks in patients with an implantable ...

BOSTON -- A leadless pacemaker reliably communicated with a subcutaneous implantable cardioverter-defibrillator (S-ICD) to deliver anti-tachycardia (ATP) and bradycardia pacing, the MODULAR ATP study ...

MARLBOROUGH, Mass., May 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System, ...

Medtronic plc (NYSE:MDT) announced longer-term follow-up results of its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) System, designed to treat dangerously fast heart ...

Please provide your email address to receive an email when new articles are posted on . Among patients who received implantable cardioverter defibrillator therapy, the subcutaneous or transvenous ...

In patients with an implantable cardioverter defibrillator (ICD), the life-saving therapeutic shocks also come to be a major cause of patient morbidity. Now the results of a clinical trial presented ...

Programming an implantable cardioverter-defibrillator (ICD) with a long-detection interval compared with a standard-detection interval resulted in a reduction in anti-tachycardia pacing episodes, ICD ...

SAN FRANCISCO — An implantable cardioverter defibrillator (ICD) with a lead system that inserts just below the sternum performed promisingly in a recent early experience that sets the stage for a more ...

EV-ICD defibrillation lead placed outside of heart and veins, preserving vasculature DUBLIN, Feb. 17, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) has received CE (Conformité Européenne) Mark for the ...

(RTTNews) - Boston Scientific Corp. (BSX) announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM System, the first modular cardiac rhythm management ...